Biologics

The first cases of Triojection, a system intended to produce ozone gas for spinal disc herniations and manufactured by Minimus Spine, were performed in Germany by Thomas Vogl, MD.

Sacramento, Calif.-based Molecular Matrix received FDA 510(k) clearance for Osteo-P, a bone graft substitute technology.

Philadelphia-based University of Pennsylvania Health system researchers at the McKay Orthopaedic Research Laboratory are developing new tissue engineering approaches to improve treatment for meniscus tears, the most common form of orthopedic surgery.

Roger Hartl, MD, director of spinal surgery and neurotrauma at Weill Cornell Brain and Spine Center in New York City and director of the Weill Cornell Medicine Center for Comprehensive Spine Care, offers two key thoughts on where spine surgery…

Michael Gordon, MD, a spine surgeon with Hoag Orthopedic Institute in Irvine, Calif., weighs in on trends he sees with regard to the use of spinal biologics.

Shelton, Conn.-based Spine Wave launched the GraftMag Graft Delivery System.

Surgeons have implanted 50 Bone Solutions' OsteoCrete.

Technavio analysts identified the top three trends of the global spinal biologics market between 2018 and 2022.

Cellular Biomedicine Group partnered with GE Healthcare to accelerate its stem cell therapy manufacturing timeline.

Former North American Spine Society President William Watters, MD, of Houston Medical, discusses the biggest spine technology, clinical and business trends for 2018.